Biotech | August 07, 2021
Sanofi to acquire Translate Bio
Advances deployment of mRNA technology across vaccines and therapeutics development
Advances deployment of mRNA technology across vaccines and therapeutics development
Miels will formally assume the role on January 1, 2026
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Revenue increased 11.4 per cent to Rs. 8,545 crore
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Subscribe To Our Newsletter & Stay Updated
